

## **David Wetherell Joins Burrill & Company Venture Capital Group as Managing Director**

Douglas Lind and Joshua Zelig also added to the firm's roster

SAN FRANCISCO, January 5, 2011—Burrill & Company is pleased to announce that David Wetherell, a veteran entrepreneur and venture capitalist, has joined the Burrill Venture Capital Group as a Managing Director. Along with Wetherell, Douglas Lind, MD, joined the firm as a Managing Director and Joshua Zelig joined as a Director.

“We are pleased to welcome David to our venture group. He brings an unusual depth of experience as an entrepreneur, CEO and venture investor,” says G. Steven Burrill, CEO of Burrill & Company. “Along with Douglas and Josh, these new additions strengthen our venture team.”

Wetherell has spent 20 years as a CEO in high-tech, as well as 17 years in venture capital, the last seven of which have been dedicated to biotech and life sciences. From 1986 to 2006, he served as both CEO and, later, chairman of CMGI, where he helped build the company from \$3 million in annual revenues to more than \$1 billion and started the first venture capital firm focused on the Internet, @Ventures. When CMGI, now ModusLink, turned its direction away from the Internet to cleantech venture investing and supply chain management, Wetherell turned his attention to the life sciences industry. In 2005, he started GBP Capital, a venture capital company focused exclusively on leading edge life sciences. Wetherell has received numerous awards, including Ernst & Young's New England Entrepreneur of the Year in 2000 and recognition as one of Money Magazine's Top 25 investors. He obtained his B.A. in Mathematics from Ohio Wesleyan University and an honorary doctorate from Bryant University. He currently serves as chairman of Lentigen and sits on the boards of numerous other companies, including HyperMed, Flexible Stenting Solutions, TMune Therapeutics and Quintess.

Dr. Lind previously served as Managing Director at GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. He has more than 20 years of experience in the life sciences industry, ranging from the practice of clinical medicine to work as a top tier Wall Street equity research analyst and venture capitalist. Throughout his career he has focused on visionary leadership and identifying promising disruptive technologies that offer high value solutions to pressing medical needs. He served as senior U.S. biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. He is a graduate of the University of Iowa College of Medicine and served as an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine, where he completed residency training in internal medicine. He currently serves on the boards of Lentigen, MabVax, TMune, HyperMed Imaging, and Spectral Image.

Zelig was an associate partner at GBP Capital. He was responsible for sourcing, evaluating and executing investment transactions and new business opportunities. Additionally, he managed the firm's intellectual property portfolios, oversaw the company's operations, and worked closely with portfolio companies in setting and delivering on strategic objectives. Prior to that, he served as an equity research associate at Morgan Stanley, where he covered biotech and consumer

stocks. He later worked in real estate management, acquisition and due diligence capacities on behalf of a number of large private real estate companies as well as public REITs. Zelig is a graduate of Yeshiva University, Sy Syms School of Business, where he received a Bachelor of Science in Finance. He is currently a member of the board of directors of Flexible Stenting Solutions.

**About Burrill & Company**

Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With \$1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: [www.burrillandco.com](http://www.burrillandco.com).

**Contact:**

Daniel Levine  
Managing Director  
Burrill & Company  
[dlevine@b-c.com](mailto:dlevine@b-c.com)  
415-591-5449